Insider Selling: Journey Medical Co. (NASDAQ:DERM) CEO Sells 18,147 Shares of Stock

Journey Medical Co. (NASDAQ:DERM) CEO Claude Maraoui sold 18,147 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $5.13, for a total transaction of $93,094.11. Following the sale, the chief executive officer now directly owns 2,092,874 shares of the company’s stock, valued at approximately $10,736,443.62. The trade was a 0.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Claude Maraoui also recently made the following trade(s):

• On Monday, March 3rd, Claude Maraoui sold 23,508 shares of Journey Medical stock. The shares were sold at an average price of $5.19, for a total transaction of $122,006.52.

Journey Medical Trading Up 3.2 %

Shares of DERM stock opened at $5.23 on Thursday. Journey Medical Co. has a 1 year low of $2.85 and a 1 year high of $6.89. The firm has a fifty day moving average price of $4.54 and a 200-day moving average price of $5.07. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03. The company has a market cap of $109.25 million, a price-to-earnings ratio of -5.56 and a beta of 0.96.

Institutional Investors Weigh In On Journey Medical

A number of hedge funds have recently modified their holdings of the business. Nwam LLC purchased a new position in shares of Journey Medical during the 3rd quarter valued at $59,000. Kovitz Investment Group Partners LLC purchased a new position in shares of Journey Medical during the 3rd quarter valued at $66,000. Cetera Investment Advisers lifted its stake in shares of Journey Medical by 21.8% during the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock valued at $54,000 after buying an additional 2,478 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Journey Medical during the 4th quarter valued at $80,000. Finally, Citadel Advisors LLC purchased a new position in shares of Journey Medical during the 4th quarter valued at $174,000. Institutional investors own 7.25% of the company’s stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.